<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03501940</url>
  </required_header>
  <id_info>
    <org_study_id>PROS0083</org_study_id>
    <secondary_id>NCI-2018-00479</secondary_id>
    <secondary_id>PROS0083</secondary_id>
    <secondary_id>IRB-42701</secondary_id>
    <nct_id>NCT03501940</nct_id>
  </id_info>
  <brief_title>F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer</brief_title>
  <official_title>18F-DCFPyL PET/CT in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-Contributory CT Scans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrei Iagaru</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      This phase II trial studies how well fluorine F 18 DCFPyL positron emission
      tomography/computed tomography (PET/CT) works in imaging participants with prostate cancer
      that has come back. Diagnostic procedures, such as fluorine F 18 DCFPyL PET/CT, may help find
      and diagnose prostate cancer and find out how far the disease has spread.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate fluorine F 18 DCFPyL (18F-DCFPyL) PET/CT for detection of recurrent prostate
      cancer after initial therapy in patients with elevated prostate-specific antigen (PSA).

      OUTLINE:

      Participants receive fluorine F 18 DCFPyL intravenously (IV). After 60-120 minutes,
      participants undergo whole body PET/CT. Immediately after the first scan, participants may
      undergo a second PET/CT without receiving fluorine F 18 DCFPyL.

      After completion of study, participants are followed up at 24-72 hours.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>PSA Level Greater Than 0.2</condition>
  <condition>PSA Level Greater Than or Equal to Two</condition>
  <condition>PSA Progression</condition>
  <condition>Recurrent Prostate Carcinoma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo 18F-DCFPyL PET/CT</description>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fluorine F 18 DCFPyL</intervention_name>
    <description>Given IV</description>
    <other_name>18F-DCFPyL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo 18F-DCFPyL PET/CT</description>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven prostate adenocarcinoma

          -  Rising PSA after definitive therapy with prostatectomy or radiation therapy (external
             beam or brachytherapy)

               -  Post radical prostatectomy (RP) - American Urological Association (AUA)
                  recommendation

                    -  PSA greater than 0.2 ng/mL measured after at least 6 weeks from radical
                       prostatectomy

                    -  Confirmatory persistent PSA greater than 0.2 ng/mL (total of two PSA
                       measurements greater than 0.2 ng/mL)

               -  Post-radiation therapy - American Society for Radiation Oncology (ASTRO) -
                  Phoenix consensus definition

                    -  A rise of PSA measurement of 2 or more ng/mL over the nadir

          -  Able to provide written consent

          -  Karnofsky performance status of &gt; 50 (or Eastern Cooperative Oncology Group [ECOG] /
             World Health Organization [WHO] equivalent)

        Exclusion Criteria:

          -  Unable to provide informed consent

          -  Inability to lie still for the entire imaging time

          -  Inability to complete the needed investigational and standard-of-care imaging
             examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

          -  Any additional medical condition, serious intercurrent illness, or other extenuating
             circumstance that, in the opinion of the Investigator, may significantly interfere
             with study compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei Iagaru</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Cancer Institute Palo Alto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jordan Cisneros</last_name>
    <phone>(650)-725-6409</phone>
    <email>jordan.cisneros@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Cancer Institute Palo Alto</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrei Iagaru</last_name>
      <phone>650-725-4711</phone>
      <email>aiagaru@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Andrei Iagaru</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2018</study_first_submitted>
  <study_first_submitted_qc>April 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrei Iagaru</investigator_full_name>
    <investigator_title>Associate Professor of Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

